Scientific publications

Modulating T Cell Responses by Targeting CD3

Feb 13, 2024 | Magazine: Cancers

Ashwathi Puravankara Menon 1 2, Beatriz Moreno 1, Daniel Meraviglia-Crivelli 1 2, Francesca Nonatelli 1, Helena Villanueva 1 2, Martin Barainka 1 2, Angelina Zheleva 1 2, Hisse M van Santen 3, Fernando Pastor 1 2


Harnessing the immune system to fight cancer has become a reality with the clinical success of immune-checkpoint blockade (ICB) antibodies against PD(L)-1 and CTLA-4. However, not all cancer patients respond to ICB.

Thus, there is a need to modulate the immune system through alternative strategies for improving clinical responses to ICB. The CD3-T cell receptor (TCR) is the canonical receptor complex on T cells. It provides the "first signal" that initiates T cell activation and determines the specificity of the immune response. The TCR confers the binding specificity whilst the CD3 subunits facilitate signal transduction necessary for T cell activation.

While the mechanisms through which antigen sensing and signal transduction occur in the CD3-TCR complex are still under debate, recent revelations regarding the intricate 3D structure of the CD3-TCR complex might open the possibility of modulating its activity by designing targeted drugs and tools, including aptamers. In this review, we summarize the basis of CD3-TCR complex assembly and survey the clinical and preclinical therapeutic tools available to modulate CD3-TCR function for potentiating cancer immunotherapy.

CITA DEL ARTÍCULO Cancers (Basel). 2023 Feb 13;15(4):1189. doi: 10.3390/cancers15041189.

Our authors

Investigadora del Programa de Terapias Moleculares del Cima Universidad de Navarra
Dr. Beatriz Moreno Bruna
Daniel Hackbrett Meraviglia-Crivelli de Caso
Helena Villanueva Ruiz
Dr. Angelina Zheleva